Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 5/2012

01.10.2012 | Transplantation (A Pileggi, Section Editor)

Risks, Benefits, and Therapeutic Potential of Hematopoietic Stem Cell Transplantation for Autoimmune Diabetes

verfasst von: Carlos Eduardo Barra Couri, Maria Carolina de Oliveira, Belinda Pinto Simões

Erschienen in: Current Diabetes Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Type 1 diabetes mellitus is a chronic disease that results from the autoimmune response against pancreatic insulin producing β cells. Apart of several insulin regimens, since the decade of 80s various immunomodulatory regimens were tested aiming at blocking some steps of the autoimmune process against β cell mass and at promoting β cell preservation. In the last years, some independent research groups tried to cure type 1 diabetes with an “immunologic reset” provided by autologous hematopoietic stem cell transplantation in newly diagnosed patients, and the majority of patients became free form insulin with increasing levels of C-peptide along the time. In this review, we discuss the biology of hematopoietic stem cells and the possible advantages and disadvantages related to the high dose immunosuppression followed by autologous hematopoietic stem cell transplantation.
Literatur
1.
Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest. 2001;108:1247–52.PubMed
2.
The Diabetes Control and Complications Trial Research Group. The effect of intensive insulin therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–9.CrossRef
3.
The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. Ann Intern Med. 1998;128:517–23.
4.
Couri CE, Foss MC, Voltarelli JC. Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting beta-cell regeneration. Braz J Med Biol Res. 2006;39:1271–80.PubMedCrossRef
5.
Lee S, Krause DS. Adult Stem Cell Plasticity. In: Burt RK, Marmont A, editors. Stem cell therapy for autoimmune disease, Chapter 11. Austin: Landes Biosciences; 2004. p. 59–76.
6.
Nagano K, Yoshida Y, Isobe T. Cell surface biomarkers of embryonic stem cells. Proteomics. 2008;8:4025–35.PubMedCrossRef
7.
Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton's Jelly, amnion and chorion. Cell Mol Biol Lett. 2011;16:493–514.PubMedCrossRef
8.
Volarevic V, Ljujic B, Stojkovic P, Lukic A, Arsenijevic N, Stojkovic M. Human stem cell research and regenerative medicine-present and future. Br Med Bull. 2011;99:155–68.PubMedCrossRef
9.
Hipp J, Atala A. Sources of stem cells for regenerative medicine. Stem Cell Rev. 2008;4:3–11.PubMedCrossRef
10.
Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009;27:2624–6.PubMedCrossRef
11.
12.
Carvalho MM, Teixeira FG, Reis RL, Sousa N, Salgado AJ. Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine. Curr Stem Cell Res Ther. 2011;6:221–8.PubMedCrossRef
13.
Pozzilli P, Di Mario U. Autoimune diabetes not requiring insulin at diagnosis (latent autoimune diabetes of the adult). Diabetes Care. 2001;24:1460–7.PubMedCrossRef
14.
American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2012;35:S4–10.CrossRef
15.
Bennett ST, Todd JA. Human type 1A diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet. 1996;30:343–70.PubMedCrossRef
16.
Fairweather DL, Rose NR. Type 1 diabetes: virus infection or autoimmune disease? Nat Immunol. 2002;3:338–40.PubMedCrossRef
17.
Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750–4.PubMedCrossRef
18.
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–300.PubMedCrossRef
19.
Eizirik DL, Mandrup-Poulsen T. A choice of death: the signal transduction of immune-mediated β-cell apoptosis. Diabetologia. 2001;44:2115–33.PubMedCrossRef
20.
Eizirik DL, Kutlu B, Rasschaert J, Darville M, Cardozo AK. Use of microarray analysis to unveil transcription factor and gene networks contributing to β-cell dysfunction and apoptosis. Am N Y Acad Sci. 2003;1005:55–74.CrossRef
21.
Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl):S97–107.PubMedCrossRef
22.
Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA. 1992;89:2804–8.PubMedCrossRef
23.
Morton JL, et al. Transplantation of autoimmune potential: development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand black mice. Proc Natl Acad Sci USA. 1974;71:2162–6.PubMedCrossRef
24.
Van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. 1996;18:1029–34.PubMed
25.
Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med. 1993;178:1607–16.PubMedCrossRef
26.
Van Bekkum DW. New opportunities for the treatment of severe autoimmune diseases: bone marrow transplantation. Clin Immunol Immunopathol. 1998;89:1–10.PubMedCrossRef
27.
Knaan-Shanzer S, Houben P, Kinwel-Bohré EP, van Bekkum DW. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant. 1991;8:333–8.PubMed
28.
Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol. 1997;24(Suppl):S23–9.
29.
Marmont AM. Coincidental autoimmune disease in patients transplanted for coincidental indications. Best Pract Res Clin Haematol. 2004;17:223–32.PubMedCrossRef
30.
Tamm M, Gratwohl A, Tichelli A, Perruchoud AP, Tyndall A. Autologous haematopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis. 1996;55:779–80.PubMedCrossRef
31.
Snowden JA, Brooks PM, Biggs JC. Haematopoietic stem cell transplantation for autoimmune disease. Br J Haematol. 1997;99:9–22.PubMedCrossRef
32.
Atkins HL, Muraro PA, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell transplantation for autoimmune disease–is it now ready for prime time? Biol Blood Marrow Transplant. 2012;18(Suppl):S177–83.PubMedCrossRef
33.
McFarland RD, Douek DC, Koup RA, Picker LJ. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci USA. 2000;97:4215–20.PubMedCrossRef
34.
Burt RK, Verda L, Oyama Y, Statkute L, Slavin S. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol. 2004;26:57–69.PubMedCrossRef
35.
de Oliveira GL, Malmegrim KC, Ferreira AF, Tognon R, Kashima S, Couri CE, et al. Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation. Clin Exp Immunol. 2012;168:291–302.
36.
Kang EM, Zickler MM, Burns S, Langemeijer SM, Brenner S, Phang AO, et al. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol. 2005;33:699–705.PubMedCrossRef
37.
Yelin EH. The economic and functional impact of rheumatic disease in the US. In: Klippel JH, Dieppe PA. editors. Rheumatology. London: Mosby International. 1998. p. 1.5.1–1.5.4.
38.
Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8:244–53.PubMedCrossRef
39.
Couri CE, Voltarelli JC. Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes. Curr Stem Cell Res Ther. 2011;6:10–5.PubMedCrossRef
40.
Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev. 2011;32:725–54.PubMedCrossRef
41.
•• Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568–76. This is the first article analyzing the safety and efficacy of autologous stem cell transplantation in humans with type 1 diabetes mellitus.
42.
•• Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573–9. This article is an update of the results previously published by Dr. Voltarelli`s group in Brazil with more patients included for a longer follow-up.
43.
• Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012;97:1729–36. This trial shows that a small number of patients who presented diabetic ketoacidosis at the time of diagnosis may stay free from insulin for some periods.
44.
• Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011;46:562–6. This article reproduces great part of the results published by Voltarelli et al.
45.
Snarski E, Torosian T, Paluszewska M, Urbanowska E, Milczarczyk A, Jedynasty K, et al. Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells. Pol Arch Med Wewn. 2009;119:422–6.PubMed
46.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, et al. Teplizumab for treatment of type 1 diabetes (protégé study):1-year results from a randomized, placebo-controlled trial. Lancet. 2011;378:487–97.PubMedCrossRef
47.
Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care. 2010;33:826–32.PubMedCrossRef
48.
Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, et al. Etanercept treatment in children with new-onset type 1 diabetes. Diabetes Care. 2009;32:1244–9.CrossRef
49.
Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial. Lancet. 2011;378:412–9.PubMedCrossRef
50.
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs β-cell function. Diabetes. 2012. doi:10.​2337/​db12-0049.
51.
Liu J, Malhotra R, Voltarelli J. Ovarian recovery after stem cell transplantation. Bone Marrow Transplant. 2008;41:275–8.PubMedCrossRef
52.
Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045–52.PubMed
53.
Tauchmanovà L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer. 2002;95:1076–84.
54.
Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Orio F Jr, Palomba S, et al. Gonadal status in reproductive age women after hematopoietic stem cell transplantation for hematological malignancies. Hum Reprod. 2003;18:1410–6.
55.
• Leal AM, Oliveira MC, Couri CE, Moraes DA, Stracieri AB, Pieroni F, et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT. Bone Marrow Transplant. 2012;47:467–8. This paper makes an update on side effects of autologous hematopoietic stem cell transplantation in gonadal function of patients included in Brazilian trial.PubMedCrossRef
56.
Au WY, Lie AK, Kung AW, Liang R, Hawkins BR, Kwong YL. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:383–8.PubMedCrossRef
57.
Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068–79.PubMedCrossRef
58.
A Trial of High Dose Immunosuppression and Autologous Hematopoietic Stem Cell Support Versus Intensive Insulin Therapy in Adults With Early Onset Type I Diabetes Mellitus. Available at: http://​www.​clinicaltrials.​gov. Accessed 15 June 2012.
Metadaten
Titel
Risks, Benefits, and Therapeutic Potential of Hematopoietic Stem Cell Transplantation for Autoimmune Diabetes
verfasst von
Carlos Eduardo Barra Couri
Maria Carolina de Oliveira
Belinda Pinto Simões
Publikationsdatum
01.10.2012
Verlag
Current Science Inc.
Erschienen in
Current Diabetes Reports / Ausgabe 5/2012
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-012-0309-0

Weitere Artikel der Ausgabe 5/2012

Current Diabetes Reports 5/2012 Zur Ausgabe

Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Influence of Type 1 Diabetes Genes on Disease Progression: Similarities and Differences Between Countries

Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Understanding Pancreas Development for β-Cell Repair and Replacement Therapies

Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Treg Vaccination with a Strong-Agonistic Insulin Mimetope

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Metabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms

Transplantation (A Pileggi, Section Editor)

Recovery of Endocrine Function After Islet and Pancreas Transplantation

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise